CA
NZ
UK
AU
IND
US
Abbott Laboratories goes ex-dividend on October 15 for a quarterly dividend of USD 0.63 per share, payable on November 16, and the board has increased its dividend payout for 54 consecutive years, making it a Dividend Aristocrat. The 2026 quarterly dividend of USD 0.63 …
Main Drivers and Recent Developments
Liquidia's October 13, 2026 release said it would not appeal the September 30 ruling and had filed a label supplement removing the indication for pulmonary hypertension associated with interstitial lung disease from Yutrepia. The settlement closes six lawsuits, with dismissals with prejudice after the …
No company announcement dated October 14, 2026 was found to explain Lilly's 3.45% advance, which appears to extend the response to its August 5 results. Revenue reached USD 22.97 billion, up 48%, with the incretin portfolio a major contributor. Mounjaro, tirzepatide for type 2 …
No Revolution Medicines announcement dated October 14, 2026 was identified to explain the 3.85% gain. R&D spending rose to USD 394.9 million from USD 224.1 million, while general and administrative costs increased to USD 110.2 million from USD 40.6 million. A warrant-related charge reflects …
No company announcement dated October 14, 2026 was found, so CAI's 4.03% rise followed the August 5 second-quarter update rather than a fresh disclosed event. Caris reported approximately 59,200 clinical cases, up about 18%, and more than 114,000 whole-exome and whole-transcriptome tests. Gross margin …
No company announcement dated October 14, 2026 was found, so Zura's 3.78% gain appears to follow the August 11 second-quarter report. The company is developing tibulizumab, an antibody targeting BAFF and IL-17 pathways, across two Phase 2 trials. General and administrative expense declined to …
No Axsome announcement dated October 14, 2026 was identified, so its 3.95% rise followed the August 10 second-quarter report. Auvelity net sales increased to USD 180.3 million from USD 119.6 million. Sunosi generated USD 35.8 million, including USD 1.5 million of royalties and USD …
No AngioDynamics announcement dated October 14, 2026 was found, so the 3.35% gain followed the October 8 fiscal first-quarter report. The company said Auryon atherectomy sales rose 14.7% to USD 18.9 million, NanoKnife irreversible-electroporation revenue climbed 29.0% to USD 8.3 million and AlphaVac mechanical …
In its October 13, 2026 announcement, Liquidia said it would not appeal the September 30 decision and had submitted a label supplement removing the pulmonary-hypertension-associated-with-interstitial-lung-disease indication from Yutrepia. The agreement settles six lawsuits, with dismissals with prejudice following the initial payment. Yutrepia will remain …
Please wait processing your request...